Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CLPP | Q16740 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14309463 | 0.92 | KMT2A (0.41) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL14309433 | 0.92 | CACNA1G (0.41) | KMT2AALDH1A1MEN1CLPP | |
| SCHEMBL14504308 | 0.91 | SMN1; SMN2 (0.41) | KMT2AKDM4EALDH1A1MEN1CLPP | |
| SCHEMBL14309919 | 0.90 | BACE1 (0.40) | CLPP | |
| SCHEMBL14309930 | 0.90 | CLPP (0.39) | KMT2AALDH1A1MEN1GAACLPP | |
| SCHEMBL14310108 | 0.90 | HDAC1 (0.39) | KMT2AKDM4EMEN1CLPP | |
| SCHEMBL13773696 | 0.90 | TP53 (0.36) | KMT2AMEN1SIGMAR1CLPPTP53 | |
| SCHEMBL14503911 | 0.90 | BACE1 (0.39) | KMT2AALDH1A1MEN1GAASIGMAR1 | |
| SCHEMBL13774093 | 0.90 | SIGMAR1 (0.39) | KMT2AALDH1A1MEN1GAASIGMAR1 | |
| SCHEMBL14310106 | 0.90 | NPC1 (0.42) | KMT2ANPC1RAB9AMEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | KMT2A 4181/4885NPC1 1370/4885RAB9A 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.